Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: J Endocrinol. 2014 Apr 29;222(1):87–97. doi: 10.1530/JOE-13-0610

Figure 8. Effect of SirT1 inhibition and AMPK activation on PAPP-A expression.

Figure 8

(A) Omental preadipocytes were treated with resveratrol (Res) (50 μM) and EX 527 (10 μM) for 24 hours. Western blotting was performed for p53 and acetylated p53.

(B) Omental preadipocytes were treated with resveratrol alone, resveratrol plus SIRT1 inhibitor EX 527 (10 μM) and EX 527 alone for 24 hours. Preadipocytes were then harvested for real-time PCR. Results (mean ± SEM, n = 3) are presented relative to control (represented by dotted line).

(C) Omental preadipocytes were treated with rolipram [25 (L) and 50 (H) μM] for 24 hours. Western blotting was performed for AMPK and phosphorylated AMPK (P-AMPK).

(D) Omental preadipocytes were treated with resveratrol or AMPK activator, rolipram (25 μM), for 24 hours. Preadipocytes were then harvested for real-time PCR. Results (mean ± SEM, n = 4) are presented relative to control (represented as dotted line).

*P < 0.05.